Vimarsana
Biggest News Aggregation in the World

Page 2 - Surgery Training News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Surgery Training. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Surgery Training Today - Breaking & Trending Today

UMMC trains Baltimore students to become surgical technicians - Vimarsana News

UMMC trains Baltimore students to become surgical technicians

Some Baltimore City school students said their future is brighter because of a special partnership with the University of Maryland Medical Center.

Source: wbaltv.com
Hearing from a FIGO Fellow, Dr Takura Kanonge - Vimarsana News

Hearing from a FIGO Fellow, Dr Takura Kanonge

Obstetric fistula is a neglected public health and human rights issue. A devastating childbirth injury that leaves women permanently incontinent unless they receive treatment by a trained, competent fistula surgeon.   

Source: figo.org
FIGO 2021 World Congress Blog – Day Five - Vimarsana News

FIGO 2021 World Congress Blog – Day Five

Exploring controversies in treatment at the Israel Forum  The fifth day of the FIGO 2021 World Congress started with a session on controversies in treatment, taking place live at the Israel Forum and streamed directly onto our virtual platform. During this session, a fascinating debate took place on the use of valaciclovir to prevent vertical transmission of cytomegalovirus. Dr Yacov Amir spoke first, taking the stance that valaciclovir is an effective form of treatment, followed by Dr Rinat Gabbay-Benziv, who argued that it has its limitations.

Source: figo.org
The Lancet: CoronaVac COVID-19 vaccine is safe and protects against disease, interim analysis - Vimarsana News

The Lancet: CoronaVac COVID-19 vaccine is safe and protects against disease, interim analysis

 E-Mail Interim data from a phase 3 trial of a COVID-19 vaccine developed in China (CoronaVac) suggests that two doses offer 83.5% protection against symptomatic COVID-19. The preliminary findings, published in The Lancet and presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), indicate that CoronaVac induces a robust antibody response. No severe adverse events or deaths were reported among the more than 10,000 trial participants in Turkey, with most adverse events mild and occurring within 7 days of an injection. However, more research is need...